Efficacy and safety of CalliSpheres drug-eluting beads for bronchial arterial chemoembolization for refractory non-small-cell lung cancer and its impact on quality of life: A multicenter prospective study
Open Access
- 14 April 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13
Abstract
Objective: This study aimed to prospectively observe the efficacy and safety of CalliSpheres drug-eluting beads bronchial arterial chemoembolization (DEB-BACE) for refractory non-small-cell lung cancer (NSCLC).Methods: The interventional therapy plan was as follows: 300–500 μm CalliSpheres drug-loaded microspheres were loaded with epirubicin, and then slow embolization of tumor supplying artery was performed after microcatheter superselection. Chest enhanced computed tomography and related hematological examination were reviewed after 2 months of DEB-BACE, and the tumor response after the first interventional therapy was evaluated using modified response evaluation criteria in solid tumors. The overall survival (OS) of patients was determined, and the quality of life and the incidence rate of adverse reactions were observed.Results: From January 2019 to January 2021, 43 patients with refractory NSCLC were enrolled. The patients were followed up until June 2022. All 43 patients underwent DEB-BACE 1.79 ± 0.69 times on average. The 3-, 6-, 12-, and 24-month survival rates were 100%, 86.0%, 41.9%, and 11.8%, respectively. The median OS was 11.5 months. After the first interventional treatment, cough and wheezing significantly improved in 31 patients, hemoptysis was effectively controlled in 12 patients, and superior vena cava compression disappeared in 2 patients after 2 times of treatment. The general health status of the patients after treatment significantly improved compared with that before treatment, including the improvement in physical and emotional functions. Fatigue, nausea and vomiting, dyspnea, and insomnia improved significantly after treatment. No serious adverse events, such as spinal cord injury and cerebral embolism, were observed during the perioperative period. The main adverse reaction after DEB-BACE was chest pain (13/43, grade 1) followed by fever (10/43, grade 1–2), which was significantly relieved within 3–5 days after symptomatic treatment. Other adverse reactions included irritating cough, nausea and vomiting, and bone marrow suppression, and the incidence was less than 20%.Conclusions: DEB-BACE was effective and safe in treating refractory NSCLC, which could significantly improve patients’ quality of life and was worthy of clinical promotion and application.Keywords
This publication has 33 references indexed in Scilit:
- Targeted Therapy and Checkpoint Immunotherapy in Lung CancerSurgical Pathology Clinics, 2020
- Definitive concurrent chemoradiotherapy outcomes in Stage IIIB nonsmall cell lung cancer patients younger than 45 years: A retrospective analysis of 145 patientsJournal of Cancer Research and Therapeutics, 2020
- Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancerMedicine, 2019
- Surgical Treatment of Lung CancerCritical Care Nursing Clinics of North America, 2019
- The efficacy of drug‐eluting beads bronchial arterial chemoembolization loaded with gemcitabine for treatment of non‐small cell lung cancerThoracic Cancer, 2019
- Short‐term efficacy, safety, and cost‐effectiveness of transarterial chemoembolization with drug‐eluting beads versus synchronous radiochemotherapy for cervical cancerInternational Journal of Gynecology & Obstetrics, 2019
- Bronchial Artery Embolization for Hemoptysis in Primary Lung Cancer: A Retrospective Review of 84 PatientsJournal of Vascular and Interventional Radiology, 2019
- Arterial Embolization in the ChestJournal of Thoracic Imaging, 1998
- Superselective Bronchial Artery Embolization for Hemoptysis with a Coaxial Microcatheter SystemJournal of Vascular and Interventional Radiology, 1997
- Distribution of Bronchial Arteries in the Human LungChest, 1972